Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CG OncologyCGON -0.23%12 Receivables Turnover is 1.10 as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, CG Oncology ranks better than 57.55% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CG Oncology's Revenue for the
three
months ended in Mar. 2026 was $1.08 Mil. CG Oncology's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.98 Mil.
Hence, CG Oncology's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.10.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CG Oncology Receivables Turnover Related Terms
CG Oncology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CG Oncology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGON vs COGT, SRRK, LGND: Receivables Turnover Comparison
For the Biotechnology subindustry, CG Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CG Oncology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology (CGON) has a Receivables Turnover of 1.10 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CG Oncology and its competitors. According to the industry distribution chart, CG Oncology ranks #357 out of 841 companies in the Biotechnology industry, placing it in the top 42.4%.
Is CG Oncology's Receivables Turnover too high?
CG Oncology's current Receivables Turnover is 1.10. The Biotechnology industry median Receivables Turnover is 5.29. CG Oncology's value of 1.10 is 79.2% below this industry median. Based on the distribution chart, CG Oncology ranks #357 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Receivables Turnover compare to COGT and SRRK?
According to the Biotechnology industry distribution chart, CG Oncology ranks #357 out of 841 companies for Receivables Turnover. This puts CG Oncology in the upper half of its industry. The industry median Receivables Turnover is 5.29. CG Oncology's value of 1.10 is 79.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Receivables Turnover of 1.10 is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CG Oncology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Receivables Turnover is 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Receivables Turnover of 1.10. The current Receivables Turnover is 1.10 and 79.2% below the Biotechnology industry median of 5.29. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CG Oncology (CGON), the current Receivables Turnover is 1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score
Get the complete analysis for CGON
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGON has been successfully added to your 
